<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609947</url>
  </required_header>
  <id_info>
    <org_study_id>IP057</org_study_id>
    <nct_id>NCT00609947</nct_id>
  </id_info>
  <brief_title>Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries.</brief_title>
  <acronym>ENDEAVORSVS</acronym>
  <official_title>A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to verify the safety and efficacy of the Endeavor&#xD;
      Zotarolimus-Eluting Coronary Stent System for improving coronary luminal diameter in patients&#xD;
      with ischemic heart disease due to de novo lesions of length ≤27 mm in native coronary&#xD;
      arteries with reference vessels ≥ 2.25 mm to ≤ 2.75 mm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-segment Percent Diameter Stenosis at 8 Months Post-procedure</measure>
    <time_frame>8 months post-procedure</time_frame>
    <description>In-segment percent diameter stenosis at 8 months post-procedure with percent diameter stenosis defined as the value calculated as 100 x (RVD - Minimal Lumen Diameter (MLD)/RVD using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiography (QCA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE) Rate</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>Major Adverse Cardiac Events rate at 12 months post-procedure defined as death, target-vessel Myocardial Infarction (Q wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization, repeat percutaneous transluminal coronary angioplasty or cardiac bypass surgery.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Endeavor Zotarolimus-Eluting Coronary Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endeavor Zotarolimus-Eluting Coronary Stent</intervention_name>
    <arm_group_label>Endeavor Zotarolimus-Eluting Coronary Stent</arm_group_label>
    <other_name>Endeavor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        GENERAL INCLUSION CRITERIA:&#xD;
&#xD;
          -  The patient is ≥18 years of age.&#xD;
&#xD;
          -  The patient has clinical evidence of ischemic heart disease, stable or unstable&#xD;
             angina, silent ischemia, or positive functional study.&#xD;
&#xD;
          -  The patient is an acceptable candidate for Percutaneous Transluminal Coronary&#xD;
             Angiography (PTCA), stenting, and emergent Coronary Artery Bypass Grafting (CABG)&#xD;
             surgery.&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative pregnancy test within 7&#xD;
             days before the procedure.&#xD;
&#xD;
          -  The patient or patient's legal representative has been informed of the nature of the&#xD;
             study and agrees to its provisions and has provided written informed consent as&#xD;
             approved by the Institutional Review Board of the respective clinical site.&#xD;
&#xD;
          -  The patient agrees to return to same research facility for all required post-procedure&#xD;
             follow-up visits.&#xD;
&#xD;
        ANGIOGRAPHIC INCLUSION CRITERIA&#xD;
&#xD;
        1. The target lesion/vessel must meet the following criteria:&#xD;
&#xD;
          1. The patient requires treatment of either:&#xD;
&#xD;
               -  A single de novo lesion located in a native coronary artery amenable to treatment&#xD;
                  with a 2.25mm, 2.5mm or 2.75mm stent, or&#xD;
&#xD;
               -  Two de novo lesions located in separate target vessels, with at least one of the&#xD;
                  target lesions amenable to treatment with a 2.25mm, 2.5mm, or 2.75mm stent and&#xD;
                  the second lesion amenable to treatment with a 2.25mm, 2.5mm, or 2.75mm stent or&#xD;
                  a 3.0mm or 3.5mm approved Endeavor stent.&#xD;
&#xD;
          2. The lesion(s) must be ≤ 27mm in length.&#xD;
&#xD;
          3. The lesion(s) must have a stenosis of ≥ 50% and &lt; 100%.&#xD;
&#xD;
          4. The vessel(s) has (have) a thrombolysis in myocardial infarction (TIMI) flow 2 or&#xD;
             greater.&#xD;
&#xD;
          5. The target vessel reference diameter must be ≥ 2.25mm and ≤ 2.75mm and the second&#xD;
             target vessel reference diameter, if present, must be ≥ 2.25mm and ≤ 3.5mm.&#xD;
&#xD;
          6. All target lesions can be treated with a Medtronic Endeavor stent.&#xD;
&#xD;
        GENERAL EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Known hypersensitivity or contraindication to aspirin, heparin, bivalirudin,&#xD;
             ticlopidine, clopidogrel, cobalt, nickel, chromium, molybdenum, polymer coatings, or&#xD;
             sensitivity to contrast media, which cannot be adequately pre-medicated&#xD;
&#xD;
          2. History of allergic reaction or significant sensitivity to drugs such as zotarolimus,&#xD;
             rapamycin, tacrolimus, everolimus, or any other analogue or derivative&#xD;
&#xD;
          3. Platelet count &lt;100,000 cells/mm³ or &gt;700,000 cells/mm³, or white blood cell count&#xD;
             &lt;3,000 cells/mm³&#xD;
&#xD;
          4. Serum creatinine level &gt;2.0 mg/dl within 7 days prior to index procedure&#xD;
&#xD;
          5. Evidence of acute MI within 72 hours of intended index procedure&#xD;
&#xD;
          6. Planned PCI of any vessel within 30 days pre or post-index procedure and/or planned&#xD;
             PCI of the target vessel(s) within 12 months post-procedure.&#xD;
&#xD;
          7. During the index procedure, the target lesion(s) requires treatment with a device&#xD;
             other than PTCA prior to stent placement&#xD;
&#xD;
          8. History of stroke or transient ischemic attack (TIA) within prior 6 months&#xD;
&#xD;
          9. Active peptic ulcer or upper gastrointestinal (GI) bleeding within prior 6 months.&#xD;
&#xD;
         10. History of bleeding diathesis or coagulopathy or patient will refuse blood&#xD;
             transfusions.&#xD;
&#xD;
         11. Concurrent medical condition with life expectancy of less than 12 months.&#xD;
&#xD;
         12. Any previous or planned treatment of target vessel with anti-restenotic therapies&#xD;
             including but not limited to brachytherapy.&#xD;
&#xD;
         13. Currently participating in an investigational drug or another device study that has&#xD;
             not completed primary endpoint or that clinically interferes with current study&#xD;
             endpoints; or requires coronary angiography, IVUS or other coronary artery imaging&#xD;
             procedures.&#xD;
&#xD;
         14. Documented left ventricular ejection fraction (LVEF) &lt;30% at most recent evaluation.&#xD;
&#xD;
         15. Inability to comply with protocol required medication regimen ANGIOGRAPHIC EXCLUSION&#xD;
             CRITERIA&#xD;
&#xD;
        1. Target lesion(s) located in native vessel distal to anastomosis with saphenous vein&#xD;
        graft or a left/right internal mammary artery bypass with &gt;40% diameter stenosis anywhere&#xD;
        within graft.&#xD;
&#xD;
        2. Previous stenting in the target vessel(s) unless the following conditions are met:&#xD;
&#xD;
        a. It has been at least 9 months since the previous stenting, and b. The target lesion(s)&#xD;
        is/are at least 15mm away from the previously placed stent.&#xD;
&#xD;
        3. Target vessel has other lesions with &gt;40% diameter stenosis based on visual estimate or&#xD;
        on-line QCA 4. Target vessel(s) has/have evidence of thrombus 5. Target vessel(s) is&#xD;
        excessively tortuous (two bends ≥90º to reach target lesion) 6. Target lesion has any of&#xD;
        the following characteristics:&#xD;
&#xD;
          1. Location is aorto-ostial, an unprotected left main lesion, or within 5 mm of the&#xD;
             origin of the left anterior descending (LAD), left circumflex (LCX), or right coronary&#xD;
             artery (RCA)&#xD;
&#xD;
          2. Involves a side branch &gt;2.0 mm in diameter&#xD;
&#xD;
          3. Is at or distal to a &gt;45º bend in the vessel&#xD;
&#xD;
          4. Is severely calcified&#xD;
&#xD;
          5. Involves a bifurcation 7. Unprotected left main coronary artery disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin B Leon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AnMed Health Medical Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 25, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <results_first_submitted>June 5, 2013</results_first_submitted>
  <results_first_submitted_qc>January 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2015</results_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited by local and regional medical centers from December 21, 2007 through November 22, 2010.</recruitment_details>
      <pre_assignment_details>Subjects were excluded from participation if they did not meet inclusion/exclusion criteria and fall into the category of per protocol small vessel stenting - 2.25mm, 2.5mm and 2.75mm - single or multi-vessel (Rev K).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Endeavor Zotarolimus-Eluting Coronary Stent</title>
          <description>Zotarolimus-eltuing stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="241"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="240">One death due to automobile accident.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Endeavor Zotarolimus-Eluting Coronary Stent</title>
          <description>Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="241"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>In-segment Percent Diameter Stenosis at 8 Months Post-procedure</title>
        <description>In-segment percent diameter stenosis at 8 months post-procedure with percent diameter stenosis defined as the value calculated as 100 x (RVD - Minimal Lumen Diameter (MLD)/RVD using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiography (QCA).</description>
        <time_frame>8 months post-procedure</time_frame>
        <population>The primary analysis sample consisted of 176 subjects (ITT) including the first 97 subjects with 2.25 mm, 39 subjects with 2.50 mm and 40 subjects with 2.75mm stents who met the study entry criteria, signed the written informed consent, and were enrolled in the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Effectiveness Analysis Endpoint - SVS</title>
            <description>The 8-month in-segment diameter stenosis from Endeavor Small Vessel Study (SVS) subects</description>
          </group>
        </group_list>
        <measure>
          <title>In-segment Percent Diameter Stenosis at 8 Months Post-procedure</title>
          <description>In-segment percent diameter stenosis at 8 months post-procedure with percent diameter stenosis defined as the value calculated as 100 x (RVD - Minimal Lumen Diameter (MLD)/RVD using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiography (QCA).</description>
          <population>The primary analysis sample consisted of 176 subjects (ITT) including the first 97 subjects with 2.25 mm, 39 subjects with 2.50 mm and 40 subjects with 2.75mm stents who met the study entry criteria, signed the written informed consent, and were enrolled in the trial.</population>
          <units>percent diameter stenosis</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4" lower_limit="16.6" upper_limit="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The 8-month in-segment percent diameter stenosis from Endeavor SVS subjects was compared to the 6-month in-segment percent diameter stenosis from Micro Driver subjects. This study assessed the superiority of SVS against the Micro-Driver regarding in-segment percent diameter stenosis at 8 months post procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The null and alternative hypotheses were:&#xD;
H0: µSVS ≥µM H1: µSVS &lt; µM where µSVS was the mean in-segment 8-month percent diameter stenosis for the SVS study and µM was the mean in-segment 6-month percent diameter stenosis for Micro-Driver.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>The sample size was not reduced below 158 evaluable subjects in order to support the analysis of the primary safety endpoint.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>49.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>21.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Cardiac Events (MACE) Rate</title>
        <description>Major Adverse Cardiac Events rate at 12 months post-procedure defined as death, target-vessel Myocardial Infarction (Q wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization, repeat percutaneous transluminal coronary angioplasty or cardiac bypass surgery.</description>
        <time_frame>12 months post-procedure</time_frame>
        <population>12-month MACE Rate was compared to a 20% performance goal.&#xD;
1st 97 subjects enrolled and implanted with 2.25mm stents&#xD;
1st 39 subjects enrolled and implanted with 2.5mm stents&#xD;
1st 40 subjects enrolled and implanted with 2.75mm stents&#xD;
A supplemental safety analysis group of subjects with 2.25mm stents N=38 (included in 2.25mm group N=135)</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Analysis Endpoint</title>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Events (MACE) Rate</title>
          <description>Major Adverse Cardiac Events rate at 12 months post-procedure defined as death, target-vessel Myocardial Infarction (Q wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization, repeat percutaneous transluminal coronary angioplasty or cardiac bypass surgery.</description>
          <population>12-month MACE Rate was compared to a 20% performance goal.&#xD;
1st 97 subjects enrolled and implanted with 2.25mm stents&#xD;
1st 39 subjects enrolled and implanted with 2.5mm stents&#xD;
1st 40 subjects enrolled and implanted with 2.75mm stents&#xD;
A supplemental safety analysis group of subjects with 2.25mm stents N=38 (included in 2.25mm group N=135)</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="10.0" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null and alternative hypotheses of interest are:&#xD;
H0: xSVS &gt;= 20% vs. H1: xSVS &lt; 20%, where x is the true SVS 12-month MACE rate.&#xD;
The assessment of the null hypothesis will be carried out at the one-sided 0.05 level of significance. Rejection of the null hypothesis indicates the SVS 12-month MACE rate is significantly below 20%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0041</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>13.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Primary Analysis Endpoint</title>
          <description>The first 97 subjects enrolled and implanted with 2.25mm stents&#xD;
The first 39 subjects enrolled and implanted with 2.5mm stents&#xD;
The first 40 subjects enrolled and implanted with 2.75mm stents&#xD;
A supplemental safety analysis group of subjects with 2.25mm stents N=38 (included in 2.25mm group N=135)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="87" subjects_affected="2" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Accute myocardial infarction</sub_title>
                <counts group_id="E1" events="87" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" events="87" subjects_affected="10" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>angina unstable</sub_title>
                <counts group_id="E1" events="87" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="87" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="87" subjects_affected="6" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="87" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Cronary artery restenosis</sub_title>
                <counts group_id="E1" events="87" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="87" subjects_affected="11" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" events="87" subjects_affected="16" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="87" subjects_affected="5" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haemorrhage</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="87" subjects_affected="16" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="87" subjects_affected="4" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="87" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="87" subjects_affected="5" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>injury</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pocket erosion</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="87" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="87" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvi-ureteric obstruction</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="87" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="87" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="87" subjects_affected="2" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="87" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="87" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lynda Chaplin - Study Manager</name_or_title>
      <organization>Medtronic CardioVascular</organization>
      <phone>(707) 543-5459</phone>
      <email>lynda.chaplin@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

